Scarica l'app Stockscreener
2.92
2.46%
0.07
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.85
Aprire:
$2.83
Volume 24 ore:
275.26K
Relative Volume:
0.42
Capitalizzazione di mercato:
$105.53M
Reddito:
$160.43M
Utile/perdita netta:
$-227.64M
Rapporto P/E:
-0.0425
EPS:
-68.77
Flusso di cassa netto:
$-170.79M
1 W Prestazione:
-0.68%
1M Prestazione:
-36.66%
6M Prestazione:
-35.68%
1 anno Prestazione:
-16.57%
Intervallo 1D:
$2.83
$3.005
Intervallo di 1 settimana:
$2.755
$3.145
Portata 52W:
$1.38
$7.34
Agenus Inc Stock (AGEN) Company Profile
Nome
Agenus Inc
Settore
Industria
Telefono
781-674-4410
Indirizzo
3 FORBES ROAD, LEXINGTON, MA
Compare AGEN vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
2.92 | 103.00M | 160.43M | -227.64M | -170.79M | -68.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-04 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-07-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-07-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-07-18 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-06-06 | Iniziato | Robert W. Baird | Outperform |
| 2023-02-28 | Ripresa | H.C. Wainwright | Buy |
| 2022-09-28 | Iniziato | SMBC Nikko | Outperform |
| 2021-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-19 | Ripresa | B. Riley FBR | Buy |
| 2019-04-22 | Iniziato | B. Riley FBR | Buy |
| 2016-10-28 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2016-10-27 | Reiterato | Maxim Group | Buy |
| 2016-03-11 | Aggiornamento | Maxim Group | Hold → Buy |
| 2015-12-16 | Iniziato | Jefferies | Buy |
| 2015-10-27 | Downgrade | Maxim Group | Buy → Hold |
| 2015-07-27 | Reiterato | MLV & Co | Buy |
| 2015-06-11 | Iniziato | Oppenheimer | Outperform |
| 2015-01-12 | Reiterato | Maxim Group | Buy |
| 2015-01-09 | Reiterato | MLV & Co | Buy |
| 2015-01-09 | Reiterato | Maxim Group | Buy |
| 2014-12-19 | Reiterato | Maxim Group | Buy |
| 2014-05-08 | Reiterato | Maxim Group | Buy |
| 2014-03-14 | Reiterato | MLV & Co | Buy |
| 2013-10-08 | Reiterato | Maxim Group | Buy |
| 2012-01-05 | Iniziato | William Blair | Outperform |
| 2011-12-01 | Iniziato | Global Hunter Securities | Buy |
Mostra tutto
Agenus Inc Borsa (AGEN) Ultime notizie
The Old System Failed Patients. Change Must Go Further and Faster – Garo Armen - Oncodaily
Why is Agenus Inc. stock going downJuly 2025 Spike Watch & Comprehensive Market Scan Insights - mfd.ru
Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors - BioSpace
Agenus Inc. (NASDAQ:AGEN) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Aug Sentiment: Why is Agenus Inc stock going downQuarterly Trade Summary & Community Supported Trade Ideas - baoquankhu1.vn
Agenus Webcast: Zydus Manufacturing Deal Closes, France Access Expands, Phase 3 BATMAN Nears Launch - MarketBeat
Agenus (AGEN) Q2 2025 Earnings Call Transcript - The Globe and Mail
Colorectal Cancer is Moving in the Wrong Direction – Agenus - Oncodaily
Agenus Strengthens Medical Affairs Infrastructure to Support Growing Authorized Access to Botensilimab–Balstilimab - Oncodaily
Agenus Lands $141M Zydus Partnership to Power BOT+BAL and U.S. Manufacturing Expansion - Oncodaily
Expansion of Global Medical Affairs to Support BOT+BAL Access – Agenus - Oncodaily
Agenus expands medical affairs to support early access to cancer therapy By Investing.com - Investing.com Nigeria
Looking Into Agenus Inc's Recent Short Interest - Benzinga
Agenus expands medical affairs to support early access to cancer therapy - Investing.com
Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab - Business Wire
Zydus Gets World’s First Menkes Disease Drug Approval Amid Ardelyx Acquisition Speculation - Citeline News & Insights
Agenus Announces First Stakeholder Webcast of 2026 Focused on BOT+BAL Program - Intellectia AI
Agenus to Host First 2026 Stakeholder Webcast - The AI Journal
Agenus signals expanded access and 2026 plans - Traders Union
Agenus Inc. (NASDAQ:AGEN) Sees Significant Increase in Short Interest - MarketBeat
FY2030 Earnings Estimate for Agenus Issued By HC Wainwright - MarketBeat
Agenus (AGEN) Q1 2025 Earnings Call Transcript - AOL.com
Zydus Completes Agenus Deal, Launches US-Based Biologics CDMO Arm Zylidac Bio - Medical Dialogues
Bear Alert: How sensitive is Agenus Inc to inflationJuly 2025 Sector Moves & Low Risk High Reward Ideas - baoquankhu1.vn
Agenus Forms Major Strategic Collaboration with Zydus Lifesciences - TipRanks
Agenus Announces the Closing of $141M Strategic Collaboration with Zydus Group - Oncodaily
Institution Moves: Will BHRPRD announce a stock splitPortfolio Risk Report & Weekly Return Optimization Plans - baoquankhu1.vn
Agenus and Zydus complete $141m BOT+BAL immunotherapy collaboration deal - Yahoo Finance
Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness - 뉴스와이어
Agenus closes strategic collaboration with Zydus Lifesciences By Investing.com - Investing.com Nigeria
Zydus LifeSciences Acquires Biologics Manufacturing Facilities from Agenus - Contract Pharma
Agenus Closes $141 Million Immunotherapy Collaboration with Zydus Lifesciences - BioPharm International
Agenus Falls After $141 Million Zydus Deal Closes - marketscreener.com
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Zydus Completes Agenus Biologics Facilities Acquisition And Launches U.S. CDMO Unit - Pulse 2.0
Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S. - StreetInsider
New Zylidac Bio sites help secure U.S. biologic drug supply chains - Stock Titan
Agenus closes strategic collaboration with Zydus Lifesciences - Investing.com
Zydus Lifesciences Completes Agenus Acquisition, Establishes Zylidac Bio LLC for US Biologics Manufacturing - scanx.trade
Agenus appoints CEO Garo Armen as interim CFO and names new accounting officer - Investing.com Nigeria
Agenus appoints CEO Garo Armen as interim CFO and names new accounting officer By Investing.com - Investing.com South Africa
Agenus Consolidates Financial Leadership With Interim CFO Appointment - TipRanks
Agenus Inc Azioni (AGEN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):